CNTB vs. ALLK, ACET, RLMD, PMVP, CTXR, CRVS, BYSI, ORMP, ASRT, and CLRB Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Allakos (ALLK), Adicet Bio (ACET), Relmada Therapeutics (RLMD), PMV Pharmaceuticals (PMVP), Citius Pharmaceuticals (CTXR), Corvus Pharmaceuticals (CRVS), BeyondSpring (BYSI), Oramed Pharmaceuticals (ORMP), Assertio (ASRT), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical preparations" industry.
Connect Biopharma (NASDAQ:CNTB ) and Allakos (NASDAQ:ALLK ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership.
Connect Biopharma has a beta of -0.49, meaning that its share price is 149% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Allakos received 165 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 59.34% of users gave Allakos an outperform vote.
In the previous week, Allakos had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 1 mentions for Allakos and 0 mentions for Connect Biopharma. Allakos' average media sentiment score of 0.06 beat Connect Biopharma's score of 0.00 indicating that Allakos is being referred to more favorably in the news media.
Connect Biopharma presently has a consensus target price of $6.50, indicating a potential upside of 265.17%. Allakos has a consensus target price of $1.83, indicating a potential upside of 27.31%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Connect Biopharma is more favorable than Allakos.
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 16.1% of Allakos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Connect Biopharma's return on equity of 0.00% beat Allakos' return on equity.
Summary Connect Biopharma beats Allakos on 7 of the 12 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Connect Biopharma Competitors List
Related Companies and Tools
